Newsroom

Servier’s VORANIGO® (vorasidenib) tablets receives FDA approval as first targeted therapy for Grade 2 IDH-mutant glioma

Boston Business Journal Names Servier Pharmaceuticals a Best Places to Work for the Fourth Consecutive Year

Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024